

---

## DIGEST

The digest printed below was prepared by House Legislative Services. It constitutes no part of the legislative instrument. The keyword, one-liner, abstract, and digest do not constitute part of the law or proof or indicia of legislative intent. [R.S. 1:13(B) and 24:177(E)]

---

HB 526 Original

2019 Regular Session

Hoffmann

**Abstract:** Adds requirements for medical assistance program coverage of opioid use disorder medications by prohibiting certain acts.

Proposed law prohibits prior authorization requirements for opioid use disorder by Medicaid and its managed care organizations for medications of any United States Food and Drug Administration (FDA) approved treatment for opioid use disorder.

Proposed law prohibits step therapy requirements prior to authorization of coverage by Medicaid and its managed care organizations for an FDA approved medication used for the treatment of opioid use disorder.

Proposed law requires for the listing of all formulations of buprenorphine/naloxone on the La. Medicaid fee-for-service drug list and the Healthy La. Common Preferred Drug List.

Proposed law prohibits excluding coverage of prescriptions and services by Medicaid and its managed care organizations that are based upon court order.

(Adds R.S. 46:460.37)